( November 6, 2025, 7:49 AM EST) -- SAN FRANCISCO — A California federal judge found that Eli Lilly and Co. failed to show that it was injured by a telehealth company selling a compounded version of tirzepatide, a Food and Drug Administration-approved drug for diabetes and weight loss, and dismissed the complaint with leave to amend....